Invivyd (Invivyd) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Invivyd FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Invivyd's Free Cash Flow for the three months ended in Mar. 2024 was $-50.35 Mil. Invivyd's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Invivyd's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Invivyd's current FCF Yield % is -79.18%.

The historical rank and industry rank for Invivyd's FCF Margin % or its related term are showing as below:

IVVD's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144.01
* Ranked among companies with meaningful FCF Margin % only.

Invivyd FCF Margin % Historical Data

The historical data trend for Invivyd's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd FCF Margin % Chart

Invivyd Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Invivyd Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Invivyd's FCF Margin %

For the Biotechnology subindustry, Invivyd's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invivyd's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Invivyd's FCF Margin % falls into.

Invivyd FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Invivyd's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-173.779	/	0
	=	%

Invivyd's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-50.354	/	0
	=	%

Invivyd FCF Margin % Related Terms

Thank you for viewing the detailed overview of Invivyd's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invivyd (Invivyd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451

Website

https://www.invivyd.com

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Executives

Adimab, Llc	10 percent owner, other: See Remarks	7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke	officer: Chief Financial Officer	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter	director	1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii	officer: Chief Scientific Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price	officer: Chief Tech. and Manuf. Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler	officer: COO & CCO	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora	officer: Chief Tech and Manuf Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt	officer: Chief Medical Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen	officer: Chief Legal Officer, Secretary	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom	director	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll	officer: Interim CFO
David Hering	director, officer: Chief Executive Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia	director, other: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp	other: See Remarks	700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell	director, 10 percent owner	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054